Glimfra MV 2 Tablet ER is a combination oral hypoglycemic agent formulated for the management of type 2 diabetes mellitus. It contains Glimepiride (2mg), Metformin (500mg), and Voglibose (0.2mg), each contributing distinct mechanisms to achieve optimal glycemic control. Glimepiride, a sulfonylurea, stimulates pancreatic beta cells to increase insulin secretion, thereby lowering blood glucose levels. Metformin, a biguanide, primarily reduces hepatic glucose production and improves peripheral insulin sensitivity, enhancing glucose uptake by muscle tissues. Voglibose, an alpha-glucosidase inhibitor, delays carbohydrate absorption in the intestines, reducing postprandial hyperglycemia. The extended-release formulation ensures a sustained and steady plasma concentration, improving patient compliance and minimizing gastrointestinal side effects commonly associated with metformin. Glimfra MV 2 is indicated for patients inadequately controlled on monotherapy or dual therapy and is used as part of a comprehensive diabetes management plan including diet and exercise. Caution is advised in patients with renal or hepatic impairment, and regular monitoring of blood glucose and renal function is recommended. Contraindications include type 1 diabetes, diabetic ketoacidosis, and hypersensitivity to any component. This combination therapy offers a multifaceted approach to glycemic control, addressing fasting and postprandial glucose elevations effectively.